miR-362-5p has also been reported to act as an oncomiR by down-regulating GADD45α, which in turn activated the JNK1/2 and P38 signaling in CML patient samples [41]. This evidence concerns the gene GADD45A and chronic myelogenous leukemia, BCR-ABL1 positive.